- Home
- MXCT
MXCT
MaxCyte Inc.
as 02-21-2025 4:00pm EST
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | ROCKVILLE |
| Market Cap: | 534.8M | IPO Year: | 2021 |
| Target Price: | $9.50 | AVG Volume (30 days): | 436.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.34 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.17 - $5.26 | Next Earning Date: | 03-11-2025 |
| Revenue: | $45,599,000 | Revenue Growth: | 19.85% |
| Revenue Growth (this year): | -6.5% | Revenue Growth (next year): | 20.23% |
Stock Insider Trading Activity of MaxCyte Inc. (MXCT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Johnston John Joseph | MXCT | Director | Jan 27 '25 | Sell | $4.65 | 3,000 | $13,935.00 | 141,950 | |
| Sandoval David I. | MXCT | GENERAL COUNSEL | Jan 13 '25 | Sell | $4.54 | 4,466 | $20,271.62 | 41,447 | |
| Johnston John Joseph | MXCT | Director | Dec 26 '24 | Sell | $4.01 | 3,000 | $12,021.00 | 141,950 | |
| Johnston John Joseph | MXCT | Director | Dec 6 '24 | Sell | $3.75 | 3,000 | $11,327.55 | 141,950 |
Latest MaxCyte Inc. News
MXCT Breaking Stock News: Dive into MXCT Ticker-Specific Updates for Smart Investing
MT Newswires
10 days ago
MaxCyte Licenses Cell-Engineering Technology to TG Therapeutics
GlobeNewswire
10 days ago
MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs
GlobeNewswire
15 days ago
MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference
MT Newswires
23 days ago
MaxCyte Acquires Gene Editing Analytics Company SeQure Dx
GlobeNewswire
23 days ago
MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments
Simply Wall St.
24 days ago
Investors push MaxCyte (LON:MXCT) 9.7% lower this week, company's increasing losses might be to blame
Zacks
a month ago
All You Need to Know About MaxCyte (MXCT) Rating Upgrade to Strong Buy
Simply Wall St.
a month ago
What Is MaxCyte, Inc.'s (LON:MXCT) Share Price Doing?
Compare MXCT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MXCT MaxCyte Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.